A comprehensive review by Cochrane concluded that the clinical benefit of anti-amyloid Alzheimer’s drugs is negligible, fueling debate among experts who say the analysis unfairly lumps together dissimilar drugs. The critique centers on mixing older failed candidates with two recently approved therapies, Leqembi and Kisunla, which have shown some slowing of cognitive decline and gained FDA approval. Critics warn that the review’s broad grouping obscures meaningful differences in drug performance. The discourse highlights the tension between modest clinical signals and the overall value of pursuing anti-amyloid strategies, with uncertainty on how to proceed for patients and regulators.
Dive Deeper:
Cochrane evaluated studies on seven monoclonal antibody drugs targeting amyloids, spanning more than a decade, to assess their clinical impact on Alzheimer’s progression.
Proponents of the newer drugs, Leqembi and Kisunla, point to slowed cognitive decline in some data, which supported FDA clearance and made them the only anti-amyloid options available.
Most of the analyzed trials involved four older drugs that failed or were never approved, plus a fifth that was withdrawn from the market, creating a heterogeneous evidence base.
Experts such as Dr. Jason Karlawish criticized the review for conflating disparate drugs, arguing that a mixed assessment produces an misleading overall takeaway.
The debate underscores broader questions about the meaningfulness of slowing decline versus achieving durable, clinically significant benefits for patients.
The discussion leaves open how clinicians should weigh modest benefits against risks and costs as new data and therapies continue to emerge.